(+)-VINCRISTINE
T Cell/Histiocyte-rich Large B-cell Lymphoma
Patrick C. Johnson, MDSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the T Cell/Histiocyte-rich Large B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Jennifer Crombie, MD | Phase 2 | CCC |
Jcar017 (Lisocabtagene Maraleucel) Patrick C. Johnson, MD | Phase 2 | CCC |
Acalabrutinib Patrick C. Johnson, MD | Phase 2 | CCC |
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →